TD raises estimatesIn a research note TD raised EPS forecast for 2022 and 2023. Obviously the interest rate outlook is not hurting HCG's bottom line.
They estimate HCG ended 2021 with $8.37 per share in excess cash, look for material buybacks and dividend in 2022.
TD has a buy rating and $53 target (unchanged).
This note I think came out yesterday (I missed it then).